IKT Stock Price, Inhibikase Therapeutics Quote, Chart

Market Summary

USD1.74-0.02

Delayed

-1.14%

IKT Stock Price

View Fullscreen

IKT RSI Chart

IKT Valuation

Market Cap

11.3M

Price/Earnings (Trailing)

-0.59

Price/Sales (Trailing)

43.26

Price/Free Cashflow

-0.7

IKT Price/Sales (Trailing)

IKT Profitability

Return on Equity

-283.34%

Return on Assets

-173.48%

Free Cashflow Yield

-141.92%

IKT Fundamentals

IKT Revenue

Revenue (TTM)

260.5K

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

IKT Earnings

Earnings (TTM)

-19.2M

Earnings Growth (Yr)

-3.84%

Earnings Growth (Qtr)

-11.29%

Breaking Down IKT Revenue

Last 7 days

32.8%

Last 30 days

-18.3%

Last 90 days

-26.3%

Trailing 12 Months

-53.7%

How does IKT drawdown profile look like?

IKT Financial Health

Current Ratio

2.55

IKT Investor Care

Shares Dilution (1Y)

25.13%

Diluted EPS (TTM)

-3.34

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	141.9K	251.8K	324.1K	260.5K
2022	2.4M	1.6M	867.7K	123.4K
2021	1.8M	3.0M	3.3M	3.1M
2020	1.0M	910.6K	804.5K	698.5K
2019	0	0	0	1.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Inhibikase Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 16, 2022	werner milton h.	bought	4,000	0.8	5,000	president and ceo
May 27, 2022	werner milton h.	bought	4,880	0.976	5,000	president and ceo
May 20, 2022	werner milton h.	bought	6,000	0.6	10,000	president and ceo
May 19, 2022	frattaroli joseph	bought	2,542	0.644	3,948	chief financial officer
Jan 03, 2022	werner milton h.	acquired	44,143	2.02	21,853	president and ceo
Nov 17, 2021	werner milton h.	bought	46,558	1.97372	23,589	president and ceo
Aug 17, 2021	werner milton h.	acquired	44,143	2.02	21,853	president and ceo
May 14, 2021	werner milton h.	acquired	16,608	0.38	43,707	president and ceo
May 14, 2021	werner milton h.	sold (taxes)	-77,653	4.59	-16,918	president and ceo
Dec 28, 2020	frattaroli joseph	acquired	441,430	10.00	44,143	chief financial officer

Which funds bought or sold IKT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	8,974	21,781	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	1,484	3,601	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-79.00	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-53.18	-1,532	5,985	-%
May 15, 2024	Royal Bank of Canada	sold off	-100	-3,000	-	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	reduced	-12.28	15,000	46,000	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	25,558	62,023	-%
May 13, 2024	UBS Group AG	new	-	6,942	6,942	-%
May 10, 2024	VANGUARD GROUP INC	reduced	-79.62	-68,073	36,124	-%
May 10, 2024	OSAIC HOLDINGS, INC.	new	-	4,320	4,320	-%

Are Funds Buying or Selling IKT?

Are funds buying IKT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IKT

No. of Funds

Unveiling Inhibikase Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 24, 2023	fivet investment management ltd	4.78%	1,341,000	SC 13D
Feb 16, 2023	werner milton h.	19.68%	5,558,912	SC 13G/A
Jan 31, 2023	fivet investment management ltd	4.12%	1,517,000	SC 13D
Feb 11, 2022	werner milton h.	21.7%	5,458,038	SC 13G/A

Recent SEC filings of Inhibikase Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 15, 2024	RW	RW
May 09, 2024	S-1/A	Initial Public Offering
May 09, 2024	S-1/A	Initial Public Offering
Apr 30, 2024	8-K	Current Report
Apr 29, 2024	S-1/A	Initial Public Offering
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 25, 2024	S-1/A	Initial Public Offering

Peers (Alternatives to Inhibikase Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Inhibikase Therapeutics Inc News

Latest updates

Inhibikase Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	-100.0%	-	1*	80.00	116	65.00	64.00	7.00	7.00	4.00	2.00	328	1,363	1,407	170	38.00	220	271	-
Costs and Expenses	8.6%	4,782	4,404	4,848	6,319	4,779	4,399	4,520	4,646	4,687	5,043	4,799	3,991	4,032	1,371	701	634	811	-
S&GA Expenses	45.0%	2,031	1,401	1,623	1,783	1,925	1,344	1,539	1,664	1,670	1,653	1,645	1,609	1,601	1,144	581	370	528	-
R&D Expenses	-8.4%	2,751	3,003	3,226	4,536	2,854	3,054	2,982	2,982	3,017	3,390	3,155	2,382	2,432	227	121	263	283	-
Interest Expenses	-41.2%	133	226	174	424	237	56.00	19.00	-	-5*	-39.69	157*	8.00	12.00	7.00	7.00	8.00	7.00	-
Net Income	-11.3%	-4,649	-4,177	-4,595	-5,777	-4,477	-4,279	-4,494	-4,639	-4,640	-5,041	-4,471	-2,636	-2,637	-1,207	-670	-421	-547	-
Net Income Margin	-0.9%	-73.71*	-73.05*	-59.03*	-75.58*	-126.06*	-146.26*	-21.68*	-11.66*	-7.13*	-4.77*	-3.35*	-2.40*	-	-	-	-	-	-
Free Cashflow	-12.3%	-3,867	-3,442	-4,105	-4,565	-5,972	-3,556	-5,704	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	-23.7%	11,068	14,507	17,881	22,347	28,163	24,936	28,581	33,992	38,390	42,470	45,869	49,216	11,874	14,783	-
Current Assets	-23.9%	10,808	14,211	17,551	21,984	27,629	24,371	27,986	33,949	-	42,470	-	-	11,871	14,783	35.00
Cash Equivalents	-74.3%	2,353	9,165	14,861	1,905	3,957	7,189	5,782	32,212	36,611	40,750	44,846	46,837	9,610	13,954	18.00
Net PPE	-9.0%	67.00	73.00	80.00	87.00	231	237	242	43.00	-	-	-	-	-	-	-
Liabilities	21.6%	4,291	3,529	2,863	2,883	2,842	3,901	3,445	4,490	4,380	4,054	2,708	2,162	3,837	4,998	4,528
Current Liabilities	23.1%	4,233	3,439	2,742	2,733	2,664	3,695	3,213	-	-	4,054	2,708	1,913	3,589	4,722	4,253
Shareholder's Equity	-38.3%	6,777	10,978	15,018	19,464	25,285	21,035	25,136	29,502	34,009	38,416	43,161	47,054	8,037	9,784	-
Retained Earnings	-7.0%	-71,550	-66,900	-62,722	-58,127	-52,349	-47,871	-43,592	-39,098	-34,458	-29,817	-24,776	-20,304	-17,668	-15,031	-12,183
Additional Paid-In Capital	0.6%	78,322	77,872	77,735	77,588	77,474	68,798	68,677	68,575	68,442	68,208	67,912	67,334	25,695	24,806	7,686
Shares Outstanding	4.7%	6,477	6,186	5,360	5,291	5,176	4,224	4,223	4,224	4,201	4,193	2,645	1,859	-	-	-
Float	-	-	-	-	19,100	-	-	-	18,700	-	-	-	51,400	-	-	-

Cashflow (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	-12.3%	-3,867	-3,442	-4,105	-4,565	-5,972	-3,556	-5,504	-4,355	-3,934	-4,095	-2,020	-4,246	-3,934	-946	76.00	-2.91	-255	-
Share Based Compensation	-56.3%	53.00	122	130	125	123	100	102	133	123	266	352	322	591	154	140	140	140	-
Cashflow From Investing	-56.5%	-3,311	-2,115	17,061	2,550	-5,838	4,963	-20,925	-43.09	-	-	-	-	-	-	-	-	-	-
Cashflow From Financing	365.7%	367	-138	70*	-35.99	8,579	-	-	-	-204	-	30.00	41,473	-409	14,884	-67.13	-2.45	250	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

IKT Income Statement

2024-03-31

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 0	$ 64,521
Revenue from Contract with Customer, Product and Service [Extensible List]	us-gaap:GrantMember	us-gaap:GrantMember
Costs and expenses:
Research and development	$ 2,751,279	$ 2,854,119
Selling, general and administrative	2,031,081	1,925,351
Total costs and expenses	4,782,360	4,779,470
Loss from operations	(4,782,360)	(4,714,949)
Interest income	132,725	237,171
Net loss	(4,649,635)	(4,477,778)
Other comprehensive income, net of tax
Unrealized (loss) gains on marketable securities	(2,677)	61,104
Comprehensive loss	$ (4,652,312)	$ (4,416,674)
Net loss per share - basic	$ (0.73)	$ (0.98)
Net loss per share - diluted	$ (0.73)	$ (0.98)
Weighted average number of common share basic	6,340,697	4,585,013
Weighted average number of common share Diluted	6,340,697	4,585,013

IKT Balance Sheet

2024-03-31

Condensed Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 2,353,346	$ 9,165,179
Marketable securities	7,396,009	4,086,873
Accounts receivable	0	0
Prepaid research and development	207,422	219,817
Prepaid expenses and other current assets	851,057	739,179
Total current assets	10,807,834	14,211,048
Equipment and improvements, net	66,804	73,372
Right-of-use asset	193,460	222,227
Total assets	11,068,098	14,506,647
Current liabilities:
Accounts payable	1,293,755	646,767
Lease obligation, current	151,159	150,095
Accrued expenses and other current liabilities	2,507,589	2,259,955
Insurance premium financing payable	280,614	381,784
Total current liabilities	4,233,117	3,438,601
Lease obligation, net of current portion	58,330	90,124
Total liabilities	4,291,447	3,528,725
Commitments and contingencies (see Note 13)
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized; 6,476,844 and 6,186,280 shares issued and outstanding at March 31, 2024 and December 31, 2023	6,477	6,186
Additional paid-in capital	78,322,334	77,871,584
Accumulated other comprehensive (loss) income	(1,800)	877
Accumulated deficit	(71,550,360)	(66,900,725)
Total stockholders' equity	6,776,651	10,977,922
Total liabilities and stockholders' equity	$ 11,068,098	$ 14,506,647

About Inhibikase Therapeutics Inc

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

CEO	Dr. Milton H. Werner Ph.D.
WEBSITE	inhibikase.com
INDUSTRY	Biotechnology
EMPLOYEES	6

Inhibikase Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Inhibikase Therapeutics Inc? What does IKT stand for in stocks?

IKT is the stock ticker symbol of Inhibikase Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Inhibikase Therapeutics Inc (IKT)?

As of Fri May 17 2024, market cap of Inhibikase Therapeutics Inc is 11.27 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IKT stock?

You can check IKT's fair value in chart for subscribers.

What is the fair value of IKT stock?

You can check IKT's fair value in chart for subscribers. The fair value of Inhibikase Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Inhibikase Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IKT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Inhibikase Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether IKT is over valued or under valued. Whether Inhibikase Therapeutics Inc is cheap or expensive depends on the assumptions which impact Inhibikase Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IKT.

What is Inhibikase Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, IKT's PE ratio (Price to Earnings) is -0.59 and Price to Sales (PS) ratio is 43.26. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IKT PE ratio will change depending on the future growth rate expectations of investors.